標簽歸檔：de

Lucigen | LGC代理,ClearColi BL21(DE3) Electrocompetent Cells,部分現(xiàn)貨

發(fā)表于由

ClearColi BL21(DE3) Electrocompetent Cells

Eliminate endotoxin at the source with this unique engineered E. coli strain for low-endotoxin protein expression.

Product Details

Each ClearColi? BL21(DE3) Electrocompetent Cell Kit contains: ClearColi BL21(DE3) Electrocompetent Cells in DUO packaging (2 transformations per tube), Expression Recovery Medium (lactose minus), pUC19 Positive Control Plasmid, and complete protocols.

Expression Recovery Medium (lactose minus) is also available separately.

Key features

  • Eliminate endotoxin at the source
  • Genetically modified LPS does not trigger endotoxic response in human cells
  • Ideal for mammalian cell immunogenicity testing, toxicity assays, and therapeutic protein drug discovery
  • Useful for membrane and lipid binding protein production
  • Protein expression similar to BL21(DE3) cells without requiring downstream endotoxin removal
  • Reduce false positives in cytokine assays, improve confidence in your results

Select a Size

Please select a Size

Lucigen | LGC, Biosearch Technologies主要開發(fā)各類用于基因克隆的試劑盒及相關(guān)產(chǎn)品，包括：CloneSmart?平端克隆試劑盒、BigEasy?線性克隆系統(tǒng)、pEZSeq™平端克隆試劑盒、聚合酶及E.cloni?感受態(tài)細胞及蛋白表達系統(tǒng)等。

Lucigen公司憑借其獨到的產(chǎn)品技術(shù)，過硬的產(chǎn)品質(zhì)量，良好的產(chǎn)品服務贏得了全球廣大用戶的信賴。此外，Lucigen還是全球科學家青睞的Epicentre品牌產(chǎn)品的供應商。在2018年，Lucigen被LGC收購，從而加強了其在基因組市場的試劑供應。Lucigen的產(chǎn)品和服務已經(jīng)覆蓋了臨床診斷、藥物開發(fā)、合成生物學和基因編輯等多個領(lǐng)域。更多產(chǎn)品信息歡迎訪問Lucigen | LGC, Biosearch Technologies官網(wǎng)。